Poster Presentation The Annual Scientific Meeting of the Australian Diabetes Society and the Australian Diabetes Educators Association 2013

Patients are more likely to reach A1c target at any given time during 26 weeks' treatment with liraglutide compared with both sitagliptin and exenatide (#372)

Robert Ratner 1 , Claus Bo Svendsen 2 , Monet Sifford-Wilson 3 , Eduard Montanya 4 , Mirella Daja 5
  1. MedStar Research Institute, Hyattsville, MD, USA
  2. Novo Nordisk A/S, Søborg, Denmark
  3. Novo Nordisk Inc, Princeton, NJ, USA
  4. IDIBELL-Hospital Universitari Bellvitge, Barcelona, Spain
  5. Novo Nordisk, Baulkham Hills, NSW, Australia

Objective: Timely attainment of target A1c levels improves patient adherence during intensification of type 2 diabetes (T2D) therapy.

Methods: In a post-hoc analysis, we analyzed proportions of patients reaching ADA target A1c <7.0% at 12, 20, and 26 weeks in two Phase 3b trials: liraglutide (n=233) vs. exenatide BID (n=231) (LEAD-6) and liraglutide OD (1.2 mg: n=221 and 1.8 mg: n=218) vs. sitagliptin OD (n=219) (LIRA–DPP-4). The "time to A1c target” was further analyzed by a Cox proportional hazards model with treatment and previous OAD treatment as fixed effects, and baseline A1c as covariate.

Results: First time to A1c target data demonstrated that a greater proportion of patients achieved glycemic target with liraglutide than with exenatide BID or sitagliptin. In LEAD-6, the estimated odds ratio was 1.50 [95% CI: 1.17; 1.92]; estimated chance of reaching target during the treatment period is 50% higher with liraglutide 1.8 mg than with exenatide BID (p<0.0068). In LIRA–DPP-4, odds ratios were 1.76 [95% CI: 1.32; 2.34] and 2.13 [95% CI: 1.62; 2.82] for liraglutide 1.2 and 1.8 mg compared with sitagliptin, respectively (p<0.0030; p<0.0001).

Discussion: We demonstrate that the timely achievement of target A1c levels is more likely with liraglutide compared with sitagliptin or exenatide BID.

Conclusion: Treatment adherence with liraglutide may be greater compared with sitagliptin or exenatide BID when used to intensify T2D therapy in patients not at target A1c.